Related resources
Full-text held externally
- PMID: 23733252
- UKPMCID: 23733252
- DOI: 10.1007/s10689-013-9661-8
Search for item elsewhere
University researcher(s)
Academic department(s)
Mammographic surveillance in women aged 35-39 at enhanced familial risk of breast cancer (FH02).
Evans, D G; Thomas, S; Caunt, J; Roberts, L; Howell, A; Wilson, M; Fox, R; Sibbering, D M; Moss, S; Wallis, M G; Eccles, D M; ; Duffy, S
Familial cancer. 2013;.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 23733252
- UKPMCID: 23733252
- DOI: 10.1007/s10689-013-9661-8
Abstract
Although there have been encouraging recent studies showing a potential benefit from annual mammography in women aged 40-49 years of age with an elevated breast cancer risk due to family history there is little evidence of efficacy in women aged <40 years of age. A prospective study (FH02) has been developed to assess the efficacy of mammography screening in women aged 35-39 years of age with a lifetime breast cancer risk of ≥17 % who are not receiving MRI screening. Retrospective analyses from five centres with robust recall systems identified 47 breast cancers (n = 12 in situ) with an interval cancer rate of 15/47 (32 %). Invasive tumour size, lymph node status and current vital status were all significantly better than in two control groups of unscreened women (including those with a family history) recruited to the POSH study. Further evaluation of the prospective arm of FH02 is required to assess the potential added value of digital mammography and the cancer incidence rates in moderate and high risk women in order to inform cost effectiveness analyses.